Invex Therapeutics Ltd. (AU:IXC) has released an update.
Invex Therapeutics Ltd. has concluded the IIH EVOLVE Phase III clinical trial for Exenatide, with the final data now publicly available, while maintaining their Orphan Drug Designations for market exclusivity in the US and Europe. The company received a significant R&D tax incentive from the UK government and continues to explore the drug’s potential for treating Traumatic Brain Injury, alongside evaluating corporate partnerships to enhance shareholder value.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.
